Evidence map›Paper›PMID 34984527›Full record

ArticleArchives of dermatological research2022

Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort.

Ronald Berna, Nandita Mitra, Ole Hoffstad, Bradley Wubbenhorst, Katherine L Nathanson, David J Margolis

Open access · greenAbstract read
In one paragraph

Article in Archives of dermatological research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Uncommon Variants inJID innovations : skin science from molecules to population health · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ronald BernaDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ronald.berna@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0003-0520-1218
Nandita MitraDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7714-3910
Ole HoffstadDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-0261-903X
Bradley WubbenhorstDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0001-8489-3659
Katherine L NathansonDivision of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-6740-0901
David J MargolisDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-0506-8085
University of Pennsylvania · US

Funding

Atopic Dermatitis and High Resolution HLAR01AR070873 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MARGOLIS, DAVID, MONOS, DIMITRI S · 2017 to 2022
$2.4M
African-Americans with Atopic Dermatitis: Skin Barrier and ImmuneR01AR069062 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MARGOLIS, DAVID · 2016 to 2021
$2.4M
NIAMS NIH HHS NIAMS R01-AR070873NIAMS NIH HHS R01 AR069062NIAMS NIH HHS R01 AR070873
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a relapsing inflammatory skin disease; filaggrin (FLG) variation has been consistently associated with its pathogenesis. Filaggrin-2 (FLG2) and trichohyalin-like-1 (TCHHL1) are members of the same protein family (S100 fused-type proteins), are similar in structure to FLG, and may be involved in AD pathogenesis. We sought to evaluate the association between variation in FLG2, TCHHL1 and AD remission. We sequenced FLG2 and TCHHL1 in a longitudinal AD cohort using targeted capture-based massively parallel sequencing. Association between individual alleles and AD remission was evaluated with generalized estimating equations for binary outcomes. Association between groups of alleles and AD remission was evaluated using a genetic algorithm to group alleles. We identified two loss-of-function (LoF) mutations in FLG2 (Ser2377Ter, Arg2207Ter) and 2 LoF mutations in TCHHL1 (Gln656Ter, Gln294Ter), none of which were associated with AD remission. Common (MAF > 5%) alleles in FLG2 were similarly unassociated with AD. No common alleles in TCHHL1 were associated with AD remission after multiple testing correction. Among self-described whites, a group of 34 uncommon alleles in FLG2 were associated with increased AD remission (OR 7.64e17; 95% CI 4.41e17-1.32e18; adjusted p < 1.0e-16). Twelve uncommon alleles in TCHHL1 trended toward association with increased AD remission (OR 23.46; 95% CI 7.07-77.89; adjusted p = 0.064). Among self-described African Americans, 13 uncommon FLG2 alleles were associated with increased AD remission (OR 21.01; 95% CI 11.90-37.09; adjusted p < 1.0e-16). No TCHHL1 uncommon allele groups were associated with AD remission among African Americans. Our study supports the role of uncommon alleles in FLG2 and TCHHL1 in AD pathogenesis.

Indexed as

Dermatitis, AtopicAllelesCohort StudiesFilaggrin ProteinsHumansIntermediate Filament ProteinsMutationS100 ProteinsWhite PeopleFilaggrin ProteinsFLG2 protein, humanIntermediate Filament ProteinsS100 ProteinsTCHHL1 protein, humanAtopic dermatitisEpidemiologyEpidermal barrier functionEpidermal biologyFilaggrin 2Population geneticsS100 fused-type proteinsTrichohyalin-like-1

Identifiers

PMID34984527
PMCPMC9250940
OpenAlexW4205811896

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.